ACCOLADE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.35 USD | +1.52% |
|
+11.31% | -22.15% |
| Apr. 22 | Stifel Adjusts Accolade's Price Target to $13 From $15, Keeps Buy Rating | MT |
| Mar. 19 | Accolade, Inc. Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President | CI |
Financials (USD)
| Sales 2024 * | 413M | Sales 2025 * | 493M | Capitalization | 724M |
|---|---|---|---|---|---|
| Net income 2024 * | -99M | Net income 2025 * | -94M | EV / Sales 2024 * | 1.26 x |
| Net cash position 2024 * | 204M | Net cash position 2025 * | 195M | EV / Sales 2025 * | 1.07 x |
| P/E ratio 2024 * |
-7.08
x | P/E ratio 2025 * |
-7.95
x | Employees | 2,370 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.01% |
More Fundamentals
* Assessed data
More news
Latest transcript on Accolade, Inc.
More recommendations
More press releases
| 1 day | +1.52% | ||
| 1 week | +11.31% | ||
| Current month | -10.78% | ||
| 1 month | -1.48% | ||
| 3 months | -20.29% | ||
| 6 months | +39.14% | ||
| Current year | -22.15% |
1 week
8.64
9.67
1 month
7.9210.68
Current year
7.9215.36
1 year
6.3317.01
3 years
4.6155.47
5 years
4.6165.25
10 years
4.6165.25
| Managers | Title | Age | Since |
|---|---|---|---|
Rajeev Singh
CEO | Chief Executive Officer | 56 | 15-09-30 |
Stephen Barnes
DFI | Director of Finance/CFO | 53 | 15-01-31 |
Robert Cavanaugh
PSD | President | 55 | 15-11-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Hilton
BRD | Director/Board Member | 60 | 15-11-01 |
Patricia Wadors
BRD | Director/Board Member | 59 | 20-02-23 |
Dawn Lepore
BRD | Director/Board Member | 70 | 19-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.10% | 1 M€ | 0.00% | - | |
| 0.97% | 11 M€ | -6.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 9.35 | +1.52% | 637,497 |
| 24-04-22 | 9.21 | +0.88% | 651,871 |
| 24-04-19 | 9.13 | -0.44% | 849,594 |
| 24-04-18 | 9.17 | +5.40% | 772,762 |
| 24-04-17 | 8.7 | +3.57% | 662,317 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Accolade, Inc. provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. It also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, womenâs health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.
Calendar
2024-04-24
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
9.35
USD
Average target price
14.8
USD
Spread / Average Target
+58.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.15% | 724M | |
| -13.25% | 86.34B | |
| +18.01% | 84.49B | |
| +11.97% | 29.68B | |
| -8.50% | 17.5B | |
| -1.85% | 16.67B | |
| -0.86% | 15.18B | |
| -0.81% | 12.71B | |
| +4.03% | 12.53B | |
| -30.53% | 11.89B |
- Stock Market
- Equities
- ACCD Stock
